Sofosbuvir

• Females of reproductive potential and men living with active female partners must use effective contraception during sofosbuvir combination therapy to avoid the risk of unwanted pregnancy that could result in harm to the unborn babies. • During treatment, monitoring the patient’s heart function as well as treating the symptoms and signs of decreased heartbeat such as fainting, weakness, light-headedness, breathing difficulty, confusion, and chest pain are imperative. • Patients should be monitored for HBsAg and anti-HBc before initiating sofosbuvir combination therapy to avoid the risk of reactivation of hepatitis B virus.